Literature DB >> 10865826

Inflammation and atherosclerosis. Atherosclerotic lesions in Takayasu arteritis.

F Numano1, Y Kishi, A Tanaka, M Ohkawara, T Kakuta, Y Kobayashi.   

Abstract

Takayasu arteritis is a chronic vasculitis, mainly involving the aorta and its main branches as well as the coronary and pulmonary arteries, causing stenosis and/or obstruction due to thrombus formation or dilatation due to aneurysmal formation and/or rupture of the involved arteries. These characteristic anomalies resulted from ischemia of retinal arteries due to the obstruction of cervical vessels. In Western countries this disease is also known as "pulseless disease," because the pulse is frequently absent due to the obstruction of subclavian or branchial arteries. The pathogenesis of this morbid condition is still unknown. Epidemiologically, it is found mostly in female patients and is more prevalent in Asian and Latin American countries. Affected areas consist of a mixture of both active, productive inflammatory lesions, and old fibrous lesions. Autoimmune processes stimulated by viral infection and other unknown causative factors may play an important role under these pathophysiological conditions because HLA analysis revealed a statistically significant high frequency of haplotype A24-B52-DR2 in these patients in Japan. Documentation of atherosclerotic complications in young female patients with Takayasu arteritis who are generally free from traditional atherosclerosis risk factors may be clinical evidence that inflammation is indeed an important risk factor in atherogenesis.

Entities:  

Mesh:

Year:  2000        PMID: 10865826     DOI: 10.1111/j.1749-6632.2000.tb06301.x

Source DB:  PubMed          Journal:  Ann N Y Acad Sci        ISSN: 0077-8923            Impact factor:   5.691


  20 in total

1.  Atherosclerosis in Takayasu arteritis.

Authors:  E Seyahi; S Ugurlu; R Cumali; H Balci; N Seyahi; S Yurdakul; H Yazici
Journal:  Ann Rheum Dis       Date:  2006-01-26       Impact factor: 19.103

2.  Intra-muscular arteries are also affected in Takayasu's arteritis.

Authors:  Zhi-Wei Wang; Song-Hua Li; Yong-Wei Yu; Sheng-Ming Dai
Journal:  Rheumatol Int       Date:  2012-08-03       Impact factor: 2.631

3.  Unprotected left main stent placement in a patient with Takayasu's arteritis: an unusual solution for an unusual disease.

Authors:  Offer Amir; Biswajit Kar; Andrew B Civitello; Nanthini Palanichamy; Ali Shakir; Reynolds M Delgado
Journal:  Tex Heart Inst J       Date:  2006

4.  Aortitis.

Authors:  Niveditha Mohan; Gail Kerr
Journal:  Curr Treat Options Cardiovasc Med       Date:  2002-06

Review 5.  Takayasu's arteritis.

Authors:  Antonio Fraga; Francisco Medina
Journal:  Curr Rheumatol Rep       Date:  2002-02       Impact factor: 4.592

6.  Risk factors for cardiovascular disease and endothelin-1 levels in Takayasu arteritis patients.

Authors:  Alexandre Wagner Silva de Souza; Henrique Ataíde Mariz; Edgard Torres Reis Neto; Anne Elizabeth Diniz Arraes; Neusa Pereira da Silva; Emília Inoue Sato
Journal:  Clin Rheumatol       Date:  2008-12-05       Impact factor: 2.980

7.  High frequency of lipoprotein risk levels for cardiovascular disease in Takayasu arteritis.

Authors:  Jozélio Freire de Carvalho; Eloísa Bonfá; Mailze C Bezerra; Rosa Maria Rodrigues Pereira
Journal:  Clin Rheumatol       Date:  2009-03-13       Impact factor: 2.980

8.  Association of ferritin antibodies with Takayasu arteritis.

Authors:  K Große; T Witte; F Moosig; B F Hoyer; C Lansche; R E Schmidt; N T Baerlecken
Journal:  Clin Rheumatol       Date:  2014-09-02       Impact factor: 2.980

9.  Pathogenesis of atherosclerosis: A multifactorial process.

Authors:  Raja B Singh; Sushma A Mengi; Yan-Jun Xu; Amarjit S Arneja; Naranjan S Dhalla
Journal:  Exp Clin Cardiol       Date:  2002

Review 10.  Imaging of large vessel vasculitis with (18)FDG PET: illusion or reality? A critical review of the literature data.

Authors:  Tarik Belhocine; Daniel Blockmans; Roland Hustinx; Johan Vandevivere; Luc Mortelmans
Journal:  Eur J Nucl Med Mol Imaging       Date:  2003-06-17       Impact factor: 9.236

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.